• HIV infection:
    • >35kg: 1 tab OD
    • Used in combination with other ARTs

Tablet: 300mg/300mg

Taken without regards to meals

Tenofovir: (NRTI); Analog of adenosine 5′-monophosphate that inhibits HIV-1 reverse transcriptase by competing with AMP as substrate, which results in the inhibition of viral replication

Lamivudine: Nucleoside Reverse Transcriptase Inhibitor (NRTI); Following phosphorylation, inhibits HIV reverse transcriptase by viral DNA chain termination

  • Rash
  • Hypercholesterolemia
  • Headache
  • Pain
  • Elevated CK
  • Diarrhea
  • Depression
  • Hyperamylasemia
  • Back pain
  • Fever
  • Nausea
  • Vomiting
  • Abdominal pain
  • Hematuria
  • Anxiety
  • Asthenia
  • Pneumonia
  • Elevated LFTs
  • Arthralgia
  • Myalgia
  • Insomnia
  • Dyspepsia
  • Dizziness
  • Neutropenia
  • Bone density loss
  • Lipodystrophy
  • Fatigue
  • Abnormal dreams
  • URI
  • Cough
  • Neuropathy
  • Glycosuria
  • Musculoskeletal pain
  • Anorexia
  • Pruritus
  • Increased Cr
  • Hypersensitivity to class/components
  • Recent or concurrent nephrotoxic agent use

WARNING

Severe acute exacerbations of hepatitis B reported in patients coinfected with HBV and HIV-1 and who have discontinued lamivudine or tenofovir df

  • Elvitegravir/cobicistat/emtricitabine/tenofovir df
  • Emtricitabine
  • Cidofovir

                          Drug Status

Availability Prescription only
Pregnancy Category C
Breastfeeding Nursing contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Lamivudine/Tenofovir DF 300mg/300mg Tablet 30’s Macleods Pharma Sai Pharma
Telariv 300mg/300mg Tablet 30’s Cosmos Ltd Cosmos Ltd
Tenofovir/Lamivudine 300mg/300mg Tablet 30’s Mylan Labs C/O Surgilinks Ltd Surgilinks Ltd
Tenofovir and Lamivudine 300mg/300mg Tablet 30’s Hetero Labs Unisel Ltd
Tenofovir/Lamivudine 300mg/300mg Tablet 30’s Mylan Labs C/O Surgilinks Ltd Surgilinks Ltd